Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for BioMed Research International, enter your email address in the box below.

BioMed Research International
Volume 2018, Article ID 9489163, 9 pages
https://doi.org/10.1155/2018/9489163
Review Article

A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma

Concetta Potenza,1 Nicoletta Bernardini,1 Veronica Balduzzi,1 Luigi Losco,2 Alessandra Mambrin,1 Anna Marchesiello,1 Ersilia Tolino,1 Sara Zuber,1 Nevena Skroza,1 and Ilaria Proietti1

1Dermatology Unit “Daniele Innocenzi”, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome, Italy
2Plastic Surgery Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy

Correspondence should be addressed to Concetta Potenza; ti.1amorinu@aznetop.attecnoc

Received 5 September 2017; Revised 12 December 2017; Accepted 18 February 2018; Published 2 April 2018

Academic Editor: Michel Saint-Cyr

Copyright © 2018 Concetta Potenza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Motaparthi, J. P. Kapil, and E. F. Velazquez, “Cutaneous squamous cell carcinoma: review of the eighth edition of the american joint committee on cancer staging guidelines, prognostic factors, and histopathologic variants,” Advances in Anatomic Pathology, vol. 24, no. 4, pp. 171–194, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Martorell-Calatayud, O. Sanmartín Jimenez, J. Cruz Mojarrieta, and C. Guillén Barona, “Cutaneous squamous cell carcinoma: defining the high-risk variant,” Actas Dermo-Sifiliográficas, vol. 104, no. 5, pp. 367–379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. P. S. Karia, J. Han, and C. D. Schmults, “Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012,” Journal of the American Academy of Dermatology, vol. 68, no. 6, pp. 957–966, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Birch-Johansen, A. Jensen, L. Mortensen, A. B. Olesen, and S. K. Kjr, “Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: rapid incidence increase among young Danish women,” International Journal of Cancer, vol. 127, no. 9, pp. 2190–2198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Wang, E. Jorgenson, A. S. Whittemore, and M. M. Asgari, “Susceptibility loci-associated cutaneous squamous cell carcinoma invasiveness,” Journal of Investigative Dermatology, vol. 138, no. 3, pp. 557–561, 2018. View at Publisher · View at Google Scholar
  6. L. Nissinen, M. Farshchian, P. Riihilä, and V.-M. Kähäri, “New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma,” Cell and Tissue Research, vol. 365, no. 3, pp. 691–702, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. J. J. Bonerandi, C. Beauvillain, L. Caquant et al., “Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 5, pp. 1–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. M. Hartevelt, J. N. Bouwes Bavinck, A. M. Kootte, B. J. Vermeer, and J. P. Vandenbroucke, “Incidence of skin cancer after renal transplantation in the Netherlands,” Transplantation, vol. 49, no. 3, pp. 506–509, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. F. J. Moloney, H. Comber, P. O'Lorcain, P. O'Kelly, P. J. Conlon, and G. M. Murphy, “A population-based study of skin cancer incidence and prevalence in renal transplant recipients,” British Journal of Dermatology, vol. 154, no. 3, pp. 498–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Peng, Y. Wang, Y. Hong et al., “Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis,” Oncotarget, vol. 8, no. 47, pp. 83280–83291, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Rubin, “MAPK pathway-targeted therapies: care and management of unique toxicities in patients with advanced melanoma,” Clinical Journal of Oncology Nursing, vol. 21, no. 6, pp. 699–709, 2017. View at Publisher · View at Google Scholar
  12. A. Lomas, J. Leonardi-Bee, and F. Bath-Hextall, “A systematic review of worldwide incidence of nonmelanoma skin cancer,” British Journal of Dermatology, vol. 166, no. 5, pp. 1069–1080, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. B. L. Diffey and J. A. A. Langtry, “Skin cancer incidence and the ageing population,” British Journal of Dermatology, vol. 153, no. 3, pp. 679-680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J.-C. Martinez and C. C. Otley, “The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician,” Mayo Clinic Proceedings, vol. 76, no. 12, pp. 1253–1265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Ahmed, J. Berth-Jones, S. Charles-Holmes, C. J. O'Callaghan, and A. Ilchyshyn, “Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study,” British Journal of Dermatology, vol. 143, no. 4, pp. 759–766, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. D. G. Brodland and J. A. Zitelli, “Surgical margins for excision of primary cutaneous squamous cell carcinoma,” Journal of the American Academy of Dermatology, vol. 27, no. 2, part 1, pp. 241–248, 1992. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Breuninger, T. Eigentler, and F. Bootz, “Brief guidelines—cutaneous squamous cell carcinoma,” Journal of the German Society of Dermatology, p. 10, 2012. View at Google Scholar
  18. J. A. Neville, E. Welch, and D. J. Leffell, “Management of nonmelanoma skin cancer in 2007,” Nature Clinical Practice Oncology, vol. 4, no. 8, pp. 462–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. T. M. Thissen, M. H. A. Neumann, and L. J. Schouten, “A systematic review of treatment modalities for primary basal cell carcinomas,” JAMA Dermatology, vol. 135, no. 10, pp. 1177–1183, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. T. H. Nguyen and D. Q.-D. Ho, “Nonmelanoma skin cancer,” Current Treatment Options in Oncology, vol. 3, no. 3, pp. 193–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. National Comprehensive Cancer Network, “Clinical practice guidelines in oncology. Basal cell and squamous cellskin cancers,” http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  22. Non melanoma skin cancer: guidelines for treatment and management in Australia. Clinical practice Guidelines, National Healt medical research Council, Camberra, Australia, 2002, https://www.nhmrc.gov.au/guidelines-publications/rescinded-guidelines.
  23. R. Motley, P. Kersey, and C. Lawrence, “Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma,” British Journal of Dermatology, vol. 146, no. 1, pp. 18–25, 2002. View at Publisher · View at Google Scholar
  24. H. W. Randle, “Basal cell carcinoma: Identification and treatment of the high-risk patient,” Dermatologic Surgery, vol. 22, no. 3, pp. 255–261, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Pampena, T. Palmieri, A. Kyrgidis et al., “Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): comparison between 2 different schedules,” Journal of the American Academy of Dermatology, vol. 74, no. 2, pp. 341–347, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. “Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Version I,” 2013, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  27. L. Lansbury, F. Bath-Hextall, W. Perkins, W. Stanton, and J. Leonardi-Bee, “Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies,” BMJ, vol. 347, article f6153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Veness, “The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities,” Journal of Medical Imaging and Radiation Oncology, vol. 52, no. 3, pp. 278–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Rio, E. Bardet, C. Ferron et al., “Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 3, pp. 753–757, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Voss and C. Kim-Sing, “Radiotherapy in the treatment of dermatologic malignancies,” Dermatologic Clinics, vol. 16, no. 2, pp. 313–320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. M. K. Silverman, A. W. Kopf, A. H. Gladstein, R. S. Bart, C. M. Grin, and M. J. Levenstein, “Recurrence rates of treated basal cell carcinomas: part 4: X‐ray therapy,” The Journal of Dermatologic Surgery and Oncology, vol. 18, no. 7, pp. 549–554, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. K. P. An and D. Ratner, “Surgical management of cutaneous malignancies,” Clinics in Dermatology, vol. 19, no. 3, pp. 305–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. S. C. R. Oliveira, C. M. V. Moniz, R. Riechelmann et al., “Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal,” Journal of Gastrointestinal Cancer, vol. 47, no. 1, pp. 75–81, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Endrizzi, R. L. Ahmed, T. Ray, A. Dudek, and P. Lee, “Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients,” Dermatologic Surgery, vol. 39, no. 4, pp. 634–645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Cartei, F. Cartei, G. Interlandi et al., “Oral 5-Fluorouracil in squamous cell carcinoma of the skin in the aged,” American Journal of Clinical Oncology, vol. 23, no. 2, pp. 181–184, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. K. G. Lewis, M. D. Lewis, L. Robinson-Bostom, and T. D. Pan, “Inflammation of actinic keratoses during capecitabine therapy,” JAMA Dermatology, vol. 140, no. 3, pp. 367-368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. A. D. Colevas, S. Adak, P. C. Amrein, J. J. Barton, R. Costello, and M. R. Posner, “A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck,” Annals of Oncology, vol. 11, no. 5, pp. 535–539, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Hoff, R. Ansari, G. Batist et al., “Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study,” Journal of Clinical Oncology, vol. 19, no. 8, pp. 2282–2292, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Denic, “Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin,” American Journal of Clinical Oncology, vol. 22, no. 1, pp. 32–34, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Khansur and A. Kennedy, “Cisplatin and 5‐fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin,” Cancer, vol. 67, no. 8, pp. 2030–2032, 1991. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Merimsky, M. Neudorfer, E. Spitzer, and S. Chaitchik, “Salvage cisplatin and adriamycin for advanced or recurrent basal or squamous cell carcinoma of the face,” Anti-Cancer Drugs, vol. 3, no. 5, pp. 481–484, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Phan, L. Phan, L. E. Ginsberg, G. Blumenschein, M. D. Williams, and B. Esmaeli, “Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread,” JAMA Ophtalmology, vol. 127, no. 8, pp. 1074-1075, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. H. Guthrie and E. S. Porubsky, “Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum iii and doxorubicin,” The Laryngoscope, vol. 92, no. 11, pp. 1298-1299, 1982. View at Google Scholar · View at Scopus
  44. T. H. Guthrie, L. J. McElveen, E. S. Porubsky, and J. D. Harmon, “Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin,” Cancer, vol. 55, no. 8, pp. 1629–1632, 1985. View at Publisher · View at Google Scholar · View at Scopus
  45. T. H. Guthrie Jr., E. S. Porubsky, M. N. Luxenberg, K. J. Shah, K. L. Wurtz, and P. R. Watson, “Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy,” Journal of Clinical Oncology, vol. 8, no. 2, pp. 342–346, 1990. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Di Monta, C. Caracò, E. Simeone et al., “Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis,” Journal of Translational Medicine, vol. 15, no. 1, article 82, 2017. View at Publisher · View at Google Scholar · View at Scopus
  47. E. W. Rudnick, S. Thareja, and B. Cherpelis, “Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies,” International Journal of Dermatology, vol. 55, no. 3, pp. 249–258, 2016. View at Publisher · View at Google Scholar
  48. S. Gil, M. Yébenes, J. Luelmo, M. Alsina, and M. Sabés, “A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: potential chemotherapy alternative to surgery,” Dermatologic Therapy, vol. 29, no. 5, pp. 341–344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Shin, B. S. Glisson, F. R. Khuri et al., “Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer,” Journal of Clinical Oncology, vol. 20, no. 2, pp. 364–370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Maubec, P. Duvillard, V. Velasco, B. Crickx, and M. F. Avril, “Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin,” Anticancer Reseach, vol. 25, no. 2, pp. 1205–1210, 2005. View at Google Scholar · View at Scopus
  51. C. M. Lewis, B. S. Glisson, L. Feng et al., “A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 18, no. 5, pp. 1435–1446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Maubec, P. Petrow, I. Scheer-Senyarich et al., “Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin,” Journal of Clinical Oncology, vol. 29, no. 25, pp. 3419–3426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. D. J. Kim, M. Lee, K. Liu et al., “Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC,” Carcinogenesis, vol. 38, no. 11, pp. 1136–1146, 2017. View at Publisher · View at Google Scholar
  55. T. Damps, A. K. Laskowska, T. Kowalkowski et al., “The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment,” PLoS ONE, vol. 12, no. 8, Article ID e0184034, 2017. View at Publisher · View at Google Scholar · View at Scopus
  56. K. P. Papadopoulos, T. K. Owonikoko, M. L. Johnson et al., “REGN2810: a fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study,” Journal of Clinical Oncology, vol. 35, no. 15, pp. 9503–9503, 2017. View at Google Scholar
  57. A. F. Nahhas, C. A. Scarbrough, and S. Trotter, “A review of the global guidelines on surgical margins for nonmelanoma skin cancers,” Journal of Clinical and Aesthetic Dermatology, vol. 10, no. 4, pp. 37–46, 2017. View at Google Scholar · View at Scopus
  58. M. C. Suzanne, R. B. Diane, and M. C. Brett, “AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery,” Journal of the American Academy of Dermatology, vol. 67, no. 4, pp. 531–550, 2012, Erratum in: Journal of the American Academy of Dermatology, vol 72, no.4, pp. 748, 2015. View at Publisher · View at Google Scholar
  59. Y. H. Jesse and L. Michael, Ramsey Cancer, Squamous Cell, Skin, StatPearls Publishing LLC, 2017.
  60. T. Fu, S. Z. Aasi, and S. T. Hollmig, “Management of high-risk squamous cell carcinoma of the skin,” Current Treatment Options in Oncology, vol. 17, no. 7, p. 34, 2016. View at Publisher · View at Google Scholar
  61. B. G. Ashford, J. Clark, R. Gupta, N. G. Iyer, B. Yu, and M. Ranson, “Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: a search for prognostic markers and therapeutic targets,” Head & Neck, vol. 39, no. 7, pp. 1462–1469, 2017. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Shen, S. A. Stass, and F. Jiang, “MicroRNAs as potential biomarkers in human solid tumors,” Cancer Letters, vol. 329, no. 2, pp. 125–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Mizrahi, A. Barzilai, D. Gur-Wahnon et al., “Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes,” Oncogene, vol. 37, no. 2, pp. 218–230, 2017. View at Publisher · View at Google Scholar